CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) indication: medical termination of pregnancy
The CADTH Canadian Drug Expert Committee (CDEC) recommends that mifepristone and misoprostol be reimbursed for medical termination of a developing intrauterine pregnancy
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that mifepristone and misoprostol be reimbursed for medical termination of a developing intrauterine pregnancy |
---|---|
Item Description: | "Notice of Final Recommendation - April 18, 2017." |
Physical Description: | 1 PDF file (5 pages) |